Interview with Dr James Garner, CEO of Kazia Therapeutics

XR-17 is Vivesto’s proprietary delivery platform

CEO corner

Get to learn more about Francois Martelet, our CEO

Vivesto published its Q1 2022 report on May 25, 2022, at 08.00 am CET.

The Share

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Annual Report 2021